First United Bank Trust Boosts Stake in Bristol-Myers Squibb Co (BMY)

First United Bank Trust increased its position in Bristol-Myers Squibb Co (NYSE:BMY) by 2.9% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 39,188 shares of the biopharmaceutical company’s stock after purchasing an additional 1,100 shares during the period. Bristol-Myers Squibb accounts for about 1.6% of First United Bank Trust’s holdings, making the stock its 18th biggest holding. First United Bank Trust’s holdings in Bristol-Myers Squibb were worth $2,401,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. Blue Chip Partners Inc. lifted its holdings in shares of Bristol-Myers Squibb by 0.7% in the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 15 shares during the last quarter. Jackson Grant Investment Advisers Inc. lifted its holdings in shares of Bristol-Myers Squibb by 0.4% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 15 shares during the last quarter. Chilton Investment Co. LLC raised its stake in Bristol-Myers Squibb by 0.5% during the 2nd quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock valued at $294,000 after acquiring an additional 26 shares during the last quarter. Keel Point LLC raised its stake in Bristol-Myers Squibb by 0.6% during the 2nd quarter. Keel Point LLC now owns 6,325 shares of the biopharmaceutical company’s stock valued at $352,000 after acquiring an additional 39 shares during the last quarter. Finally, Hudock Capital Group LLC raised its stake in Bristol-Myers Squibb by 0.4% during the 2nd quarter. Hudock Capital Group LLC now owns 11,775 shares of the biopharmaceutical company’s stock valued at $656,000 after acquiring an additional 49 shares during the last quarter. 69.56% of the stock is owned by institutional investors and hedge funds.

Several analysts have commented on BMY shares. Credit Suisse Group reaffirmed a “hold” rating and set a $61.00 price objective (up from $58.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $60.00 price objective on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Leerink Swann upped their price objective on Bristol-Myers Squibb from $61.00 to $72.00 and gave the company an “outperform” rating in a research note on Monday, October 23rd. Zacks Investment Research raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Friday, January 19th. Finally, Vetr downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price objective for the company. in a research note on Thursday, February 8th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $65.58.

Bristol-Myers Squibb Co (NYSE:BMY) opened at $65.35 on Thursday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb Co has a 52-week low of $51.56 and a 52-week high of $66.10. The stock has a market capitalization of $106,960.00, a P/E ratio of 110.76, a price-to-earnings-growth ratio of 1.96 and a beta of 1.08.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 33.68% and a net margin of 4.85%. The company had revenue of $5.45 billion for the quarter, compared to analysts’ expectations of $5.35 billion. During the same quarter in the previous year, the firm posted $0.63 EPS. The firm’s quarterly revenue was up 3.9% on a year-over-year basis. sell-side analysts forecast that Bristol-Myers Squibb Co will post 3.22 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Shareholders of record on Friday, January 5th were given a dividend of $0.40 per share. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Thursday, January 4th. This represents a $1.60 annualized dividend and a yield of 2.45%. Bristol-Myers Squibb’s payout ratio is presently 271.19%.

In related news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the sale, the executive vice president now owns 9,251 shares in the company, valued at approximately $585,033.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares in the company, valued at approximately $37,031,717.01. The disclosure for this sale can be found here. Insiders own 0.23% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “First United Bank Trust Boosts Stake in Bristol-Myers Squibb Co (BMY)” was first posted by Week Herald and is owned by of Week Herald. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://weekherald.com/2018/02/15/first-united-bank-trust-boosts-stake-in-bristol-myers-squibb-co-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply